| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
90,630,000 |
| Market
Cap: |
13.92(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$129.52 - $265 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 664 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
100,397 |
1,200,397 |
5,371,251 |
5,588,274 |
| Total Sell Value |
$15,909,372 |
$214,459,372 |
$1,041,558,017 |
$1,085,894,829 |
| Total People Sold |
2 |
3 |
8 |
9 |
| Total Sell Transactions |
6 |
7 |
21 |
54 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Oyler John |
Chief Executive Officer |
• • – |
2020-08-14 |
4 |
AS |
$209.55 |
$1,838,034 |
D/D |
(8,705) |
0 |
|
20% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-08-13 |
4 |
AS |
$211.01 |
$3,097,762 |
D/D |
(14,443) |
0 |
|
22% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-08-12 |
4 |
AS |
$209.38 |
$4,203,766 |
D/D |
(19,820) |
0 |
|
24% |
|
| Chen Timothy Yung-Cheng |
Director |
– • – |
2020-08-12 |
4 |
S |
$212.00 |
$614,165 |
D/D |
(2,897) |
0 |
|
-24% |
|
| Chen Timothy Yung-Cheng |
Director |
– • – |
2020-08-12 |
4 |
OE |
$31.59 |
$91,516 |
D/D |
2,897 |
2,897 |
|
- |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2020-08-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,560 |
7,201,009 |
|
- |
|
| Chen Timothy Yung-Cheng |
Director |
– • – |
2020-08-11 |
4 |
S |
$212.41 |
$405,409 |
D/D |
(1,903) |
0 |
|
-25% |
|
| Chen Timothy Yung-Cheng |
Director |
– • – |
2020-08-11 |
4 |
OE |
$31.59 |
$60,116 |
D/D |
1,903 |
1,903 |
|
- |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2020-08-10 |
4 |
AS |
$208.91 |
$844,229 |
I/I |
(4,000) |
0 |
|
25% |
|
| Chen Timothy Yung-Cheng |
Director |
– • – |
2020-08-10 |
4 |
S |
$212.34 |
$470,886 |
D/D |
(2,200) |
0 |
|
-25% |
|
| Chen Timothy Yung-Cheng |
Director |
– • – |
2020-08-10 |
4 |
OE |
$31.59 |
$69,498 |
D/D |
2,200 |
2,200 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-08-05 |
4 |
AS |
$218.96 |
$3,852,273 |
D/D |
(17,254) |
0 |
|
9% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-08-04 |
4 |
AS |
$216.63 |
$3,390,951 |
D/D |
(15,383) |
0 |
|
7% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-08-03 |
4 |
AS |
$212.53 |
$5,583,575 |
D/D |
(25,176) |
0 |
|
3% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2020-07-29 |
4 |
AS |
$208.35 |
$629,787 |
D/D |
(3,000) |
0 |
|
7% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2020-07-29 |
4 |
OE |
$29.49 |
$284,835 |
D/D |
3,000 |
3,000 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-07-22 |
4 |
AS |
$235.26 |
$6,613,503 |
D/D |
(27,748) |
0 |
|
-4% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-07-21 |
4 |
AS |
$248.12 |
$6,651,695 |
D/D |
(26,413) |
0 |
|
-1% |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2020-07-20 |
4 |
AS |
$249.78 |
$3,015,740 |
I/I |
(12,000) |
0 |
|
1% |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2020-07-20 |
4 |
AS |
$249.60 |
$1,259,896 |
D/D |
(5,000) |
0 |
|
1% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-07-20 |
4 |
AS |
$248.70 |
$7,243,784 |
D/D |
(28,762) |
0 |
|
1% |
|
| Wu Xiaobin |
President & GM China |
• – – |
2020-07-20 |
4 |
AS |
$250.16 |
$650,407 |
D/D |
(2,600) |
0 |
|
1% |
|
| Wu Xiaobin |
President & GM China |
• – – |
2020-07-17 |
4 |
AS |
$240.00 |
$172,015 |
D/D |
(700) |
0 |
|
15% |
|
| Baker Julian |
Director |
– • • |
2020-07-15 |
4 |
A |
$14.23 |
$207,544,549 |
I/I |
14,584,180 |
18,840,379 |
|
- |
|
| Amgen Inc |
10% Owner |
– – • |
2020-07-15 |
4 |
A |
$14.23 |
$421,442,751 |
D/D |
29,614,832 |
236,249,845 |
|
- |
|
241 Records found
|
|
Page 7 of 10 |
|
|
5.02 (3.38%) 
